Relation Therapeutics secures $35 million of new seed financing led by DCVC and co-lead NVentures, NVIDIA’s venture arm
Relation Therapeutics secures $35 million of new seed financing led by DCVC and co-lead NVentures, NVIDIA’s venture arm
- Relation Therapeutics secures $35 million of new seed financing led by DCVC and co-lead NVentures, NVIDIA’s venture arm
London, March 2024 – Relation Therapeutics, a biotechnology company at the forefront of leveraging computational and experimental approaches to drug discovery, today announced $35 million in new seed financing, bringing its total seed fundraise to $60 million. - David Roblin, CEO of Relation Therapeutics, said: "This financing is a significant milestone for Relation Therapeutics and underscores the confidence our investors have in our innovative approach to drug discovery and development.
- Our technology platform, uniquely integrated with deep R&D expertise, places us in an outstanding position to transform drug discovery.
- “We see Relation as a leader in the emerging techbio economy,” said Jason Pontin, General Partner at DCVC, who sits on Relation’s board.